paclitaxel has been researched along with ha14-1 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bradacs, G; Grabowski, P; Heine, B; Höpfner, M; Krahn, A; Maaser, K; Scherübl, H; Schuppan, D; Somasundaram, R; Stein, H; Sutter, AP; Vormbrock, K; Zeitz, M | 1 |
| Bold, RJ; Galante, JG; Gilad, O; Kung, HJ; Mortenson, MM; Schlieman, MG; Virudachalam, S | 1 |
| Arisan, ED; Basaga, H; Bodur, C; Kutuk, O; Telci, D; Tezil, T | 1 |
3 other study(ies) available for paclitaxel and ha14-1
| Article | Year |
|---|---|
Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzopyrans; Carcinoma, Hepatocellular; Cell Cycle; Cell Division; Cell Line, Tumor; Docetaxel; Doxorubicin; Drug Synergism; Enzyme Inhibitors; Humans; Isoquinolines; Ligands; Liver Neoplasms; Nitriles; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Receptors, GABA-A; RNA, Messenger; Taxoids; Tritium | 2004 |
BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Benzopyrans; Cell Line, Tumor; Cell Survival; Clone Cells; DNA, Complementary; Enzyme Activation; Enzyme Inhibitors; Genes, Reporter; Humans; Immunohistochemistry; Luciferases, Renilla; NF-kappa B; Nitriles; Paclitaxel; Pancreatic Neoplasms; Phosphorylation; Precipitin Tests; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Subcellular Fractions; Transfection | 2007 |
Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; bcl-X Protein; Benzopyrans; Breast Neoplasms; Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Nitriles; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Time Factors; Transfection | 2010 |